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Summary
Objective: To test the effectiveness of glucosamine (GluNH2)-HCl, chondroitin sulfate (CS) and mixtures in protecting cartilage exposed to
ﬁbronectin fragments (Fn-fs), an exposure known to enhance catabolic cytokines and matrix metalloproteinases (MMPs).
Methods: Pharmacologic formulations of GluNH2 (FCHG49
) and CS (TRH122) (Nutramax Laboratories, Inc.) were added at 1, 10 or
100 mg/ml singly or in mixtures to bovine cartilage cultures in serum or serum-free conditions with or without Fn-f. Proteoglycan (PG) release
into media and remaining cartilage PG content were measured by dye binding analysis and effects on PG synthesis by assays of 35-sulfate
incorporation. Effects on MMP-3 and -13 expression were measured by Western blotting of conditioned media.
Results: In serum-free conditions, the agents singly or as mixtures did not block Fn-f mediated matrix degradation. In serum, single agents were
weakly effective at 100 mg/ml, while the mixture of each agent at 0.1 mg/ml decreased PG loss by about 50% by day 7 and at 1 mg/ml restored
nearly 50% of the PG after 7 days in Fn-f pretreated cartilage. However, both agents singly and as mixtures at 0.1e100 mg/ml decreased MMP
release. In serum, the single agents at 1e10 mg/ml weakly reversed Fn-f mediated PG synthesis suppression, while the mixtures were 100%
effective at 1 mg/ml.
Conclusions: GluNH2 and CS act synergistically in reversing damage and promoting repair at concentrations found in plasma after oral inges-
tion of these agents. Reversal of PG synthesis suppression correlates more with these activities than suppression of MMP-3 or -13 expres-
sion.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Abbreviations: GluNH2 glucosamine, CS chondroitin sulfate, GAGs glycosaminoglycans, OA osteoarthritis, NSAIDs nonsteroidal anti-
inﬂammatory drugs, PG proteoglycan, MMP matrix metalloproteinase, MMP-3 stromelysin-1, Fn ﬁbronectin, Fn-f ﬁbronectin fragment,
ECL enhanced chemiluminescent, HRP horse radish peroxidase, DMEM Dulbecco’s modiﬁed Eagle’s medium, SD standard deviation,
S.E.M. standard error of mean, DMB dimethylmethylene blue.Introduction
Glucosamine (GluNH2) and chondroitin sulfate (CS) are two
commonly used nutraceutical compounds that have been
reported to have chondroprotective qualities. GluNH2 is an
amino monosaccharide precursor that is incorporated,
either directly or after conversion to galactosamine, into
the disaccharide unit of glycosaminoglycans (GAGs) found
in proteoglycans (PGs) in the cartilage matrix. CS is a long-
chain, sulfated polymer of up to 40-kDa of repeating, par-
tially sulfated disaccharide units of galactosamine sulfate
and glucuronic acid and represents the majority of GAGs
in articular cartilage1.
Clinical trials on GluNH2 used in relief of osteoarthritis
(OA) symptoms have shown that GluNH2 has a moderate
treatment effect, whereas CS has a larger treatment
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inﬂammatory drugs (NSAIDs), GluNH2 has been reported
to be as effective as NSAIDs at relieving the symptoms of
OA5,6. Efﬁcacy depends on the measurement methodology,
with the Lequesne Index showing improvement over placebo
in many studies but no improvement when the WOMAC In-
dex is used7e9. Some studies have shown no effect, possibly
related to the source of GluNH2 used
7e9 as discussed10. CS
has also been shown to be efﬁcacious for the treatment of
mild to moderate OA11e13 and also as effective as NSAIDs
in pain reduction11. Several studies also indicated a disease
modiﬁcation potential in knees and hands12,13.
Although CS and GluNH2 are now commonly used as
a combination for treatment of OA, only a few studies
have evaluated efﬁcacy of the combination. Das and Ham-
mad14 conducted a randomized, placebo-controlled study
with 93 knee OA patients, using as the primary outcome
the Lequesne Index of Severity of OA of the Knee (ISK)
and found that the combination with added manganese
ascorbate showed signiﬁcant improvement over the pla-
cebo14. In a smaller study of subjects with degenerative
joint disease of the knee or lower back, Lefﬂer et al.15
used the same combination and showed signiﬁcant effects3
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visual analog scale for pain, and physical examination
score. A large, ongoing study (the Glucosamineechondroi-
tin Arthritis Intervention Trial, ‘‘GAIT’’)16 is currently com-
paring CS and GluNH2 hydrochloride, alone and in
combination, to a nonsteroidal cyclooxygenase-2 inhibitory
drug (NSAID) using the same source of CS used in these
two smaller studies14,15. To date, this study, which is using
the WOMAC Index, has shown that the combination is sub-
stantially more effective than either agent alone in relieving
symptoms of knee OA, even surpassing the NSAID in effec-
tiveness16. Interestingly, only those patients with moderate
to severe knee pain had a better response with the combi-
nation than with celecoxib. It remains to be seen whether or
not these results will be evident in a larger set of patients.
The speciﬁc combination of GluNH2 hydrochloride and
low molecular weight CS, with added manganese ascor-
bate, has also been studied clinically in animals and with
in vitro studies. The mixture has been shown in vitro to
act synergistically in stimulating the production of PGs in
the articular cartilage, while inhibiting the activity of the deg-
radative enzymes that act on articular cartilage17. In a study
of surgical reconstruction of canine cruciate ligament, this
formulation taken orally, stimulated cartilage metabolism
as measured by an increase in CS epitopes 3B3 and
7D418. Animal trials have also shown this combination to
exert a protective effect on cartilage degradation in various
experimental models17e20.
While the clinical effectiveness of GluNH2 and CS is con-
troversial and warrants further studies, the possible mecha-
nism(s) of action also remain a matter of controversy and
ongoing research. Reported in vitro effects of GluNH2
include stimulation of GAG synthesis21,22, inhibition of cyclo-
oxygenase independent anti-inﬂammatory properties23,24
and inhibition of IL-1 stimulated gene expression25e31 or
protease activity32. Reported effects of CS include stimula-
tion of synthesis of PG12,13,17,33, inhibition of degradative
enzymes34e36 and inhibition of IL-1 stimulated gene expres-
sion and production of pro-inﬂammatory genes including
matrix metalloproteinases (MMPs)28,29,32. Thus, each agent
has been reported to have both proanabolic and anti-cata-
bolic or anti-inﬂammatory activities.
One complication in interpretation of relevant published
studies is that many of these studies have used concentra-
tions of CS and GluNH2 far higher than the levels reported
to occur after oral ingestion. Typical concentrations of the
agents in plasma after oral ingestion are in the tens of mg/ml.
For example, pharmacokinetic studies indicate a bioavailabil-
ity ofCSup to 5e70%,with someof theCSbeing absorbedas
partially degraded components37 and maximal concentra-
tionsof 3e36 mg/ml, dependingon thespecies17,38e41. In con-
trast,GluNH2 in plasmahas very lowbioavailability, due to the
apparent effect of ﬁrst pass metabolism38,42e45. Radiotracer
studies show high uptake23,24,38,42e45 and maximal levels of
unmetabolized GluNH2 in dogs, horses, and humans of
2e11 mg/ml38,42e45. These levels are far below those often
used for in vitro studies and apparently too low to serve as
an effective, glucose-competing substrate for PG synthe-
sis23,24,38,42e47. These resultsdraw into question theassump-
tion that GluNH2 and/or CS act by providing additional
substrates for PG synthesis. However, it should also be noted
that CS given in a low mass form has been shown, like
GluNH2, to have an afﬁnity for articular cartilage
36 and thus,
serum levels of these agents may not be useful in predicting
their efﬁcacy after oral ingestion. Nonetheless, only recently
have studies on GluNH2 shown effects on chondrocytes at
lowmg/ml concentrations, andonly onestudyhasshowncleareffects of CS on inhibition of IL-1 action at the reported phys-
iological concentration28,29,31. There have also been limited
studies that have tested whether speciﬁc combinations are
more effective than the individual agents17, although it has
been postulated that combiningGluNH2 with CS yields a syn-
ergistic rather than additive effect48,49.
In order to investigate whether or not GluNH2 and CS as
single agents or as a combination at concentrations close to
those observed after oral ingestion are effective, we have
tested the GluNH2 hydrochloride and the CS used in the
GAIT study16 and also tested in other studies16,17,28,29, in
a cartilage chondrolytic culture model in which the catabolic
mediators, ﬁbronectin fragments (Fn-fs), are added to carti-
lage explants50. The Fn-fs elevate catabolic cytokines51,52
and MMPs51,53 which cause transient suppression of PG
synthesis and severe depletion of cartilage PG54. Since
the damaged bovine cartilage does not spontaneously re-
store PG after the Fn-fs are removed, this model is also
useful for tests of effects on cartilage repair (reviewed in
Ref. 55). The relevance of this model is based on our obser-
vations that Fn-fs are found in OA synovial ﬂuids and carti-
lage, that injection of Fn-f into rabbit knee joints causes
cartilage degeneration56,57 and that these Fn-fs are easily
generated under cartilage damage conditions initiated by
other catabolic mediators such as addition of MMP-3 or
IL-1 to cultured cartilage58.
Materials and methods
All common chemicals and reagents were from Sigma
Chemical Co. (St. Louis, MO). [35S] sulfate was from ICN
Biomedicals Inc. (Cosa Mesa, CA). Fetal bovine serum
was from Gibco-Invitrogen (Carlsbad, CA). Rabbit poly-
clonal antibody to the hinge region of human MMP-3
(#AB810) was from Chemicon Corporation (Temecula,
CA). Rabbit polyclonal antibody to the hinge region of hu-
man MMP-13 (#M4052) and Reactive Red 120-agarose
were from Sigma Chemical Co. (St. Louis, MO). Horse rad-
ish peroxidase (HRP) conjugated sheep anti-rabbit IgG
(A0545) was from Sigma Chemical Co. (St. Louis, MO).
The modiﬁed Lowry protein assay kit and the Enhanced
Chemiluminescent (ECL), the Super Signal Chemilumines-
cent Substrate kit for HRP, were from Pierce Chemical Co.
(Rockford, IL). The Quantikine Human MMP-3 enzyme
linked immunosorbent assay (ELISA) kit was from R & D
Systems, Inc. (Minneapolis, MN). The GluNH2 and CS
pharmacologic formulations tested (GluNH2 hydrochloride
(FCHG49) and CS (TRH122)) were from Nutramax Lab-
oratories, Inc. (Edgewood, MD). Solutions were made up
fresh at the start of the experiment and kept frozen for up
to 21 days in between use.
ISOLATION OF Fn-fs
An amino-terminal 29-kDa thrombin-generated Fn-f is the
most characterized of the Fn-fs in terms of cartilage chondro-
lytic activities55. However, for these studies, a more physio-
logically relevant mixture of Fn-fs was the major type of Fn-f
studied. The mixture was derived by digestion of human
plasma ﬁbronectin with 1 mg/ml MMP-3 and contains Fn-fs
of 29-kDa, 40e60-kDa and 120e160-kDa, and has been
described elsewhere59. This mixture has activities indistin-
guishable from the thrombin-generated 29-kDa. In compari-
sons between the two different types of Fn-fs, assays of the
effects of the mixture on rates of PG degradation in bovine
metacarpophalangeal cartilage in DMEM cultures showed
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had approximately the same rate constant as a 1 mM solution
of the highly puriﬁed amino-terminal 29-kDa Fn-f. Themixture
at 1 mM also suppressed PG synthesis to the same level as
1 mM 29-kDa Fn-f when assayed as described54.
In order to add credibility to our use of the mixture, we
tested whether a 29-kDa band found in the mixture was sim-
ilar to the thrombin-generated 29-kDa Fn-f. The MMP-3 di-
gest mixture was subjected to electrophoresis on 10%
acrylamide gels, lightly stained with Coomassie Blue in fresh
plastic containers. Bands of 29-kDa, 50e70-kDa and
140e160-kDa were detected after light staining with Coo-
massie. The 29-kDa band was excised, subjected to trypsin
digestion and peptides analyzed by ESI-QUAD-TOF mass
spectrometry using standard protocols. The band yielded
a tryptic fragment of residues 58e67. Therefore, the small
29-kDa Fn-f in the MMP-3 digest is likely the same throm-
bin-generated 29-kDa Fn-f we have extensively studied
which contains residues 1e259.
In order to ensure that active proteinases in the Fn-f so-
lutions did not account for cartilage degradation, their ef-
fects at 1 mM concentrations on cartilage in DMEM that
had been freeze-thawed for three cycles to inactivate meta-
bolic processes were measured. None of the Fn-fs solutions
had a signiﬁcant effect on enhancing PG degradation and
release into the culture media over a 7 day period. Further,
in order to ensure that no MMP-3 activity remained in the
mixture, the MMP-3 digest was passed over reactive Reac-
tive Red 120-agarose to remove MMP-3 and then subse-
quently treated with 10 mM ethylenediaminetetraacetic
acid (EDTA), prior to a ﬁnal dialysis against phosphate buff-
ered saline (PBS). In order to ensure that trace inactive
MMP-3 in the MMP-3 digest which may have not been to-
tally removed by Reactive Red-agarose treatment would
not interfere with our MMP blotting, the 29-kDa thrombin-
generated Fn-f was utilized in experiments where media
were to be blotted against anti-MMPs. All the Fn-f solutions
were treated with detoxi-Gel prior to use, dialyzed to
remove protease inhibitors and EDTA and sterile ﬁltered.
Assays of endotoxin with a kit from Sigma Chemical Co.
showed levels <50 pg/mg of protein in any Fn-f solution.
EXPLANT CULTURES
Culturing of slices of bovine metacarpophalangeal carti-
lage from 18-month-old bovines was performed as
described54 in DMEM containing 50 U/ml penicillinestrepto-
mycin in 10% serum/DMEM or in DMEM alone and with
20e60 mg cartilage per 1.5 ml/well. The cartilage was
allowed to equilibrate for 2 days in DMEM alone prior to ad-
justment to the ﬁnal culturing conditions. During the culture,
the media were changed every other day for 10% serum/
DMEM cultures but were not changed for kinetic assays
of PG degradation in serum-free cultures. Each condition
was replicated in triplicate for each culture.
ASSAYS OF KINETICS OF PG DEGRADATION
The kinetics of PG degradation and release into the media
in serum-free cultures were studied in order to generate con-
ditions in which the damaged cartilage could not effectively
respond with enhanced anabolic activities that might have
been contributed by growth factors in serum. These condi-
tions provide tests of the effects onmostly catabolic activities.
Brieﬂy, cartilagewas preequilibrated in DMEM for 2 days and
then adjusted to various concentrations of the agents ora mixture. For the mixture, the concentrations given refer to
the concentration of each agent. After 4 h, the cultures were
adjusted to 1 mM Fn-f. The media were not changed during
the culture. Each day, for up to 5 days, 50 ml aliquots of the
culture media were removed, the media diluted 10-fold and
PG content was assayed using the dimethylmethylene blue
(DMB) assay as modiﬁed50. The PG content was converted
to mg PG/mg cartilage for each of three similar wells and the
amounts graphed vs day in culture to determine rate con-
stants of mg PG/mg cartilage/day by linear regression. Sepa-
rate assays showed thatCSwhenadded to thePGstandards
used to generate our standard curve or added to papain
digests did not increase the colorimetric response, indicating
that CS that had been added to themedia was not capable of
interfering with the assay.
ASSAYS OF EFFECTS OF AGENTS ON PG CONTENT
OF CARTILAGE IN 10% SERUM CULTURES
In order to test the effects of the agents on blocking Fn-f
mediated PG degradation as measured by the PG content
of cultured cartilage, conditions of 10% serum were used.
These conditions are more physiologic than serum-free
and are conditions in which damaged cartilage has serum
growth factors in the media which would help mount an
anabolic response to the damage as well as proteinase in-
hibitors which would decrease proteolytic damage. This lat-
ter culture system allowed us to measure effects of agents
on homeostasis closer to steady state conditions than
serum-free and thus, to measure the summation of anabolic
and catabolic events. We have shown that in these long-
term 21e28 day cultures, that cell viability as measured
by DNA content does not decrease by more than 20%, an
amount not statistically different than untreated cartilage54.
Bovine cartilage was cultured in 10% serum/DMEM with
the single agents or with a mixture and with or without
100 nM Fn-f for periods up to 21 or 28 days. For the mixture,
the concentrations given refer to the concentration of each
agent. The agents were added ﬁrst, followed by addition of
Fn-f 4 h later. Media were changed every other day. Every 7
days, the PG content of the remaining slices was measured
by DMB assays of papain digests. Each condition was rep-
licated in triplicate for each culture.
ASSAYS OF EFFECT OF AGENTS ON PG CONTENT
OF DAMAGED CARTILAGE IN 10% SERUM CULTURES
In order to test the reparative activity of the agents, carti-
lage was damaged with 100 nM Fn-f prior to addition of
agents. Brieﬂy, bovine cartilage was cultured in 10%
serum/DMEM with 100 nM Fn-f from days 0e7 to deplete
PG. Media were changed every other day. At day 7,
some of the cultures were adjusted to various concentra-
tions of GluNH2 and CS or mixtures but without Fn-f. For
the mixtures, the concentrations given refer to the concen-
trations of each component. PG content was analyzed
every 7 days. PG contents were determined on papain di-
gests using the DMB assay as described54. The PG
contents were reported as mg PG/mg wet weight cartilage.
Each condition was replicated in triplicate for each culture.
WESTERN BLOTTING AND CHEMILUMINESCENT
DETECTION OF MMPs
In order to test whether potentially beneﬁcial effects of the
agentsmight occur through the ability to suppress expression
of MMPs, Western blotting of conditioned media was
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the ability of Fn-fs to decrease PG content of cultured carti-
lage60. An aliquot of conditioned serum-freemedia, after con-
centrating 10-fold, was applied to 7.5 or 10% acrylamide
sodium dodecyl sulphate (SDS) gels run at 30 mA per gel
and the resultant gels blotted onto nitrocellulose for 1 h at
100 V. The amount of protein applied in each lane was iden-
tical and typically about 5 mg, as measured with the modiﬁed
Lowry protein assay. The blot was then treated with 3% BSA
in 20 mM Tris buffer, pH 7.4, containing 140 mM NaCl (Tris
buffered saline (TBS)) for 1 h at room temperature or over-
night at 4(C. The blot was then incubated with a 1e5000
fold dilution of anti-MMP-3 or 1e3300 for anti-MMP-13 for
1 h, washed three times with TBS containing 0.1% Tween
20 (TBST) for 5e10 min each. The blot was then reacted
with HRP conjugated rabbit anti-sheep IgG for 1 h, washed
three times with TBST and one last time with TBS. The blot
was then reacted with Supersignal West Dural Extended Du-
ration substrate (Pierce Chemical Co., Rockford, IL) for
5 min before being placed in a plastic membrane pro-
tector. The image was captured by a Lumi-Imager with
BoehringereMannheim Lumi Analyst 3.0 software.
When 10% serum conditioned media were concentrated
10-fold and subjected to blotting against anti-MMP-3, broad
heavy smears of about 70-kDa in both nontreated and Fn-f
treated samples, due to 100% serum, made visualization of
MMP-3 bands difﬁcult. As an alternative, a human MMP-3
ELISA kit was tested but no signiﬁcant reaction was noted
from any samples. As another alternative, media were ﬁrst
treated with Reactive Red 120-agarose to concentrate
MMP-3 and separate it from the serum. A 50 ml suspension
(50/50) of agarose was mixed with 1.0 ml of nonconcen-
trated conditioned media for 30 min, followed by washing
of the resin with TBS and treatment of the resin with dena-
turation buffer and reducing agent. This yielded a releasate
that when subjected to blotting yielded elevated MMP-3
bands in Fn-f treated cultures and only baseline levels in
non-Fn-f treated cultures.
ASSAYS OF EFFECTS OF AGENTS ON PG SYNTHESIS
IN EXPLANTS
In order to test whether potentially beneﬁcial effects of the
agents might occur through the ability to reverse the PG syn-
thesis suppression activity of Fn-fs54, assays of 35-S sulfate
incorporation were employed. Bovine cartilage was cultured
in 10%serum/DMEMcultures in the presence of various con-
centrations of the agents alone or as a mixture. For the mix-
ture, the concentrations given refer to the concentration of
each agent. Four hours after addition of agent, some cultures
were adjusted to 100 nM Fn-f. Media were changed every
other day. At various times, the media were adjusted to
10 mCi/ml of 35S-sodium sulfate for 2 h, followed by a 2-h
cold chase with 10% serum/DMEM. Slices were weighed
and then extracted with 1 ml of 4 M guanidine-HCl, 0.1% Tri-
ton X-100, 10 mMEDTA, 100 mM sodium acetate, pH 5.5 for
16 h, followed by exhaustive dialysis of the extracts against
10 mM EDTAewater. For explants, the amount of label was
expressed as dpm/mg wet weight cartilage and converted
into percentage of values for control untreated cultures.
Each condition was replicated in triplicate for each culture.
STATISTICAL TREATMENT
For kinetic assays of PG degradation, three wells were
used per time point in each culture and 5 days analyzedby linear regression to obtain rate constants and S.E.M.
values. An n value of 15 was used to compare slopes using
the two-tailed unpaired Student’s t test. For assays of PG
content and of PG synthesis rates, for each major culture,
cartilage was pooled from three to four bovines and three
culture wells were used for each condition. Each of the ma-
jor cultures was performed four times 1 month apart and the
ﬁnal mean and ﬁnal S.E.M. values from a total of 12 wells/da-
tum were determined as n¼ 12. In this way, the variance in
the ﬁnal analysis reﬂected as many parameters as possible,
including but not limited to, cartilage weighing variation, as-
say variation, culturing condition variations and cartilage
heterogeneity. Cartilage heterogeneity was inherent due
to well to well variation in cartilage slice masses, shapes
and original in situ joint locations, the latter of which could
theoretically introduce variability in biochemical response.
Once the ﬁnal mean and S.E.M. values were calculated,
control vs experimental data at selected time points were
compared using two-tailed unpaired Student’s t tests of
the 12 culture wells and associated S.E.M. values. This anal-
ysis allowed us to perform pairwise analysis of single time
points without assumption of a mechanism that would be
implied by analysis of data as kinetic curves. In order to
concisely describe statistical trends in a subset of data, P
values, representing the least signiﬁcance within the set
are given where possible and appropriate.
Results
GluNH2 OR CS SEPARATELY OR IN A MIXTURE
DID NOT DECREASE KINETICS OF DAMAGE
In the ﬁrst test of effects of the agents, serum-free condi-
tions were chosen such that proteinase inhibitors and
growth factors present in serum would not be able to con-
tribute a response to the damage and obscure visualization
of blocking of catabolism. Aliquots of media were removed
each day to measure PG contents so rate constants could
be estimated. Figure 1 shows that the Fn-f mixture (MMP-
3 generated) enhanced the rate of PG degradation and re-
lease into the media as compared to untreated cartilage.
Further, 100 mg/ml of either GluNH2 or CS alone had no ef-
fect on the PG release kinetics. To test protective effects,
the agents at 0.1e100 mg/ml singly or in mixtures (M)
were added to cartilage, followed 4 h later by addition of
the Fn-f mixture. The agents did not signiﬁcantly decrease
the enhanced rate caused by the Fn-f while a concentration
of 100 mg/ml signiﬁcantly increased the rate (P¼ 0.002).
Analysis of the PG remaining at the end of the experiments,
conﬁrmed that the agents did not signiﬁcantly decrease the
ability of Fn-fs to decrease PG content (data not shown).
GluNH2 OR CS OR MIXTURES ALONE SLOWED Fn-f MEDIATED
MMP-3 RELEASE
Since the data in Fig. 1 suggested that the agents did not
decrease PG catabolism, we investigated next whether this
lack of blocking correlated with lack of effect on expression
of a major MMP involved in Fn-f mediated cartilage dam-
age, MMP-360. Conditioned media from similar serum-free
cultures as in Fig. 1 were tested for MMP-3 content, except
the 29-kDa Fn-f was used instead of the Fn-f mixture in
order to avoid possible detection of trace amounts of
MMP-3 used to generate the mixture. As shown in Fig. 2,
at day 3, various conditions and concentrations of the
agents in the absence of the 29-kDa Fn-f did not enhance
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GluNH2, CS and mixtures) as compared to that of the Fn-f
control (lane F) and untreated controls (Ct). The numbers
refer to mg/ml of agent and in the case of the mixture, the
concentrations of each component. These experiments
were performed with three different cartilage preparations
with similar observations.
However, the agents paradoxically appeared to slow Fn-f
mediated MMP-3 release (Fig. 3). Each test of the agent
corresponds to a well in which the 29-kDa Fn-f was added
4 h after test agent. The blots on the left side show that ini-
tially GluNH2 and CS appeared to decrease Fn-f mediated
MMP-3 release, although this blocking is mostly lost by
day 3, although the levels are still lower at day 3 than in
Fig. 1. Effect of GluNH2 and CS and mixtures on Fn-f mediated
kinetics of PG release into media in serum-free cultures. Cartilage
was cultured in DMEM with 0.1, 1, 10 or 100 mg/ml GluNH2 (G in
ﬁgure) or CS (C in ﬁgure) or equal amounts in a mixture (M) also
in presence or absence of 100 nM of an MMP-3 generated Fn-f
mixture. The Fn-f, agent combination is shown with a plus sign.
Agents were added 4 h prior to addition of Fn-f. Aliquots of condi-
tioned media were assayed for PG content as a function of time
and plotted as mg PG/mg wet weight cartilage. Each condition
was in triplicate and each datum was plotted for each of 5 days, re-
sulting in an n value of 15 for linear regression. Linear regression
was used to estimate rates and S.E.M. values of best ﬁt curves.
Four cartilage harvests were used for the analysis.Fn-f treated controls. An anomaly is also observed, in that
1 and 10 mg/ml GluNH2 seem to be more effective than
the highest concentration. CS appeared to decrease
MMP-3 in a dose dependent fashion. The panels on the
right are for the mixture of the agents and show that the mix-
ture was also ineffective by day 3 and appeared to be
weaker than that of either of the single agents. Concentra-
tions of 0.01 and 0.1 mg/ml were also tested and found
not to decrease MMP-3 expression (data not shown). These
experiments were performed with four different cartilage
preparations with similar observations.
Since MMP-13 is also thought to be a critical MMP in-
volved in physiological cartilage degradation, it was also
probed. Figure 4 shows similar effects of GluNH2 and CS
at days 1 and 3 for MMP-13 compared to MMP-3. By day
3, there was little blocking of MMP-13 release. Thus, both
MMPs were affected similarly by the treatments with maxi-
mal MMP release delayed until day 3. Most of the lanes
for day 1 show both the higher molecular weight 60-kDa
proMMP-13 form and the active 48-kDa form, while lanes
for day 3, especially those for GluNH2 and CS additions
show only very low levels of proMMP-13, suggesting that
activation of proMMP-13 is occurring with time in the cul-
tures and that the agents do not block activation by day 3.
In contrast, the mixture at day 3 appears to show some de-
gree of blocking of activation.
Since blotting is semiquantitative, we did not attempt to
compare amounts of any of the MMPs at day 3 with the
Fn-f treated samples. The data shown do suggest that the
agents are still partially effective in blocking at day 3. None-
theless, as will be shown below the effects on MMP release
when the agents are compared to the mixture did not corre-
late with the order of their effects on blocking damage or
promoting restoration of PG.
GluNH2 OR CS ONLY WEAKLY BLOCKED Fn-f MEDIATED
PG DEPLETION IN 10% SERUM, WHILE MIXTURES
WERE MORE EFFECTIVE
The previous observations suggested that the agents
were not powerful enough to block catabolism under
serum-free conditions in the absence of serum growth fac-
tors and proteinase inhibitors. We next tested whether the
agents could block Fn-f mediated cartilage PG depletion
in the presence of serum which would provide proteinaseFig. 2. Effect of GluNH2, CS and mixtures on MMP-3 release into media. Cultures were established as in Fig. 1, except the thrombin-generated
29-kDa Fn-f was used rather than the MMP-3 digest. At day 3, media were recovered, dialyzed against water and concentrated 10. Samples
were subjected to electrophoresis, blotted and blots probed with anti-MMP-3. Shown in panel A are effects of 1,10 and 100 mg/ml GluNH2 (G in
ﬁgure) on MMP-3 release as compared with a positive control 29-kDa Fn-f treated well (F) and untreated control (Ct). Panel B shows similar
studies with CS (C in ﬁgure) and panel C shows effects of the mixture (M in ﬁgure). Panel D shows a side by side comparison of the higher
concentrations.
798 G. A. Homandberg et al.: Cartilage repair by GluNH2 and CSFig. 3. Effect of GluNH2, CS and mixtures on MMP-3 release in serum-free conditions in the presence of the 29-kDa Fn-f. Cultures were es-
tablished as in Fig. 2, except 100 nM 29-kDa Fn-f was added after a 4 h preincubation with test agents and MMP-3 content in media from days
1, 2 and 3 was visualized. Shown is an untreated control (C), a 29-kDa Fn-f treated positive control (F) and treated samples designated as in
Fig. 2. In this montage, Fn-f has been added to each agent treated well. The controls reﬂecting agent only, non-Fn-f treated cultures, are all in
Fig. 2. On the left side are GluNH2, CS treated samples and on the right, mixture treated.inhibitors to limit damage and anabolic growth factors to al-
low cartilage mediated compensation to the damage. In this
serum culture system, the PG content of the remaining car-
tilage is measured and this reﬂects not only catabolism but
the summation of catabolism and anabolism over a culture
period of up to 21 days.
Figure 5(A) shows that when cartilage was adjusted to 1,
10 or 100 mg/ml GluNH2 alone without Fn-fs, PG content
was unaffected. The apparent decrease in PG content
with 100 mg/ml of agent at days 14 and 21 was insigniﬁcant.
However, when Fn-fs were added 4 h after addition of the
agents, the 100 mg/ml concentration appeared to decrease
Fn-f mediated PG loss by days 7, 14 and 21 (P< 0.01 for
all) as compared to Fn-f treatment. A weaker protective
effect was observed for 1 and 10 mg/ml at day 7 (P¼ 0.01
for both) but only for 10 mg/ml at day 21 (P¼ 0.007). Con-
centrations of 0.01 and 0.1 mg/ml were not tested because
of the weaker effect of 1 mg/ml.CSwas tested in a similar fashion as shown in Fig. 5(B). In
this case, CS alone at any concentration had no signiﬁcant
effect on PG content. However, CS at all concentrations
appeared to diminish Fn-f mediated decreases in PG content
by day 14 and by day 21 and there also appeared to be a re-
pair response. When compared to Fn-f treatment, 1, 10 and
100 mg/ml decreased Fn-f activity, at day 7 (P¼ 0.01, 0.06,
and 0.005, respectively), at day 14 (P< 0.004) and at day
21 (P< 0.0004). Concentrations of 0.01 and 0.1 mg/ml did
not have a signiﬁcant effect (data not shown).
In contrast, Fig. 5(C) shows that mixtures of the agents at
0.1, 1, 10 and 100 mg/ml very effectively blocked Fn-f medi-
ated PG depletion at day 7 (P¼ 0.02, 0.01, 0.0005, and
0.0002, respectively). A concentration of 0.01 mg/ml was in-
effective (data not shown). For day 14, concentrations of 1,
10 and 100 mg/ml were still effective (P< 0.005), as well as
for day 21, (P< 0.001). Concentrations of 1 mg/ml (shown)
and 0.01 mg/ml had no signiﬁcant effect (data not shown).Fig. 4. Effect of GluNH2, CS and mixtures on MMP-13 release in the presence of the 29-kDa Fn-f. Cultures were established as in Fig. 2,
except 100 nM 29-kDa Fn-f was added after a 4 h preincubation with test agents and MMP-13 content in media from days 1 and 3 was tested.
Shown are untreated control (C), a positive Fn-f treated control (F) and test samples designated as in Fig. 2.
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IN DAMAGED CARTILAGE
In the next type of experiment, cartilage was damaged
ﬁrst by culture with Fn-f for 7 days, in order to test for the
ability of agents to enhance restoration of lost PG. The
Fn-f was removed at 7 days and agents added.
Figure 6(A) shows that treatment of nondamaged cartilage
with 10 or 100 mg/ml of GluNH2 alone did not have a signif-
icant effect on decreasing PG content by day 14. However,
by day 21, 10 mg/ml did decrease PG content by 11% with
Fig. 5. Effect of GluNH2, CS and mixtures on Fn-f mediated PG de-
pletion in 10% serum. Cartilage was cultured in 10% serum/DMEM
with 1, 10 or 100 mg/ml GluNH2 (G in ﬁgure) (panel A) or CS (C in
ﬁgure) (panel B) or mixtures (M in ﬁgure) (panel C) also in presence
or absence of 100 nM MMP-3 generated Fn-f. The mixture was also
tested at 0.1 mg/ml. PG content was measured every 7 days. The
curves corresponding to agent alone, in the absence of Fn-f, gen-
erally followed the linear horizontal proﬁle for the nontreated
control.
similar effects of 100 mg/ml (P< 0.0005 for both). At day 28,
10 and 100 mg/ml decreased PG content (P< 0.003 for
both) as compared to untreated control. Apparently, GluNH2
had a small but signiﬁcant effect, by itself. Adjustment of Fn-
f damaged cartilage cultures to 100 mg/ml GluNH2 at day 7,
did not signiﬁcantly increase PG content by day 14 or 21, as
compared with Fn-f treatment but did so by day 28
(P¼ 0.005). However, concentrations of 1 or 10 mg/ml had
no signiﬁcant effect at any time points. Concentrations of
0.01 and 0.1 mg/ml were not tested because of the weaker
effect of 1 mg/ml.
Figure 6(B) shows that CS alone, when added to non-
damaged cartilage, had no signiﬁcant effect on PG content
at any time points. Further, adjustment of Fn-f damaged
Fig. 6. Effect of GluNH2, CS and mixtures on reversal of Fn-f
mediated PG depletion. Cartilage was cultured in 10% serum/
DMEM with MMP-3 generated Fn-f for 7 days to decrease PG con-
tent (Fn-f(d0e7)) GluNH2 (panel A) or CS (panel B) or mixtures
(panel C) were then added at 1, 10 or 100 mg/ml, in absence of
Fn-f, to test for restoration of PG.
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signiﬁcantly increase PG content by day 14. However, by
day 21, 10 and 100 mg/ml CS did enhance PG content as
compared to Fn-f treatment alone (P¼ 0.01 and 0.001,
respectively). By day 28, the effects were greater
(P< 0.0001 for both). Concentrations of 0.01 and 0.1 mg/
ml were not tested because of the weaker effect of 1 mg/ml.
Figure 6(C) shows that mixtures of the two agents at
1e100 mg/ml when added to nondamaged cartilage did
not signiﬁcantly enhance PG content at any time point as
shown in Fig. 6(C). However, adjustment of Fn-f damaged
cartilage cultures to 10 or 100 mg/ml of the mixture at day
7, signiﬁcantly enhanced PG content by day 14 as com-
pared to Fn-f treatment alone (P< 0.002). At day 21, the
effects were still signiﬁcant for 10 and 100 mg/ml
(P< 0.0001 for both). A concentration of 1 mg/ml was also
effective (P¼ 0.003). At day 28, the effects for 1, 10 and
100 mg/ml were still signiﬁcant (P< 0.0004 for all). Concen-
trations of 0.01 and 0.1 mg/ml had no signiﬁcant effect (data
not shown).
THE AGENTS DECREASED RELEASE OF MMP-3
IN SERUM CONDITIONS
Conditioned media from the serum cultures tested for
blocking activity were probed for MMP-3 at day 7 of the cul-
ture period. This time point was chosen since we have
shown that release of MMP-3 is maximal during this pe-
riod51 as is Fn-f mediated cartilage matrix degradation54.
The puriﬁed thrombin-generated 29-kDa was used for these
studies and a Reactive Red 120-agarose capture method
was required to isolate the MMP-3 antigen from serum com-
ponents as described in Materials and methods. MMP-13
expression was not tested because of an apparent failure
of the agarose to separate MMP-13 away from serum com-
ponents. Figure 7 shows that as compared to the serum-
free data described earlier, the serum cultures allowed the
agents to decrease MMP-3 release into the media to
a much greater extent. The separate agents and mixture[Fig. 7(A,C,E)] did not enhance MMP-3 except for a slight
increase in 0.1 mg/ml CS treated cultures [Fig. 7(A)].
When the agents were tested for their ability to block Fn-f,
CS strongly blocked even at concentrations as low as
0.1 mg/ml, with a suggestion of lesser blocking as CS con-
centrations were increased. A concentration of 0.01 was
also tested and found not to decrease MMP-3 expression
(data not shown).
Similar results were observed with GluNH2 treatment as
well as treatment with the agent mixture (M). Note also
the same anomaly we described earlier for GluNH2 in se-
rum-free conditions and for all three conditions in serum
and for CS in panel B. The blocking effect is decreased
with higher concentrations of agents. This analysis for
MMP-3 release was tested with three different cartilage
preparations with similar results.
MIXTURES REVERSED Fn-f MEDIATED PG
SYNTHESIS SUPPRESSION
Since GluNH2 and CS blocked MMP release better than
the agent mixture but were relatively inactive in blocking of
PG degradation or in promotion of PG restoration, the
possibility that the mixture worked through reversal of Fn-f
mediated suppression of PG synthesis was investigated.
A complication of this analysis is that Fn-f treated cartilage
responds to the damage ﬁrst with suppression of PG syn-
thesis; however, after days 5e7, the PG synthesis rates slowly
increase to untreated control levels and above54,61,62. Thus,
the potential effects of the agents on promoting repair can
only be tested early in the culture within the ﬁrst week.
To test effects of the agents on PG synthesis in the ab-
sence of Fn-f, cartilage was treated ﬁrst with the agents
alone and the cultured slices then incubated at various
times with 35S sulfate to measure rates of incorporation
as a relative measure of PG synthesis. Figure 8(A) shows
that the higher concentrations of 10 mg/ml CS appeared to
enhance PG synthesis at days 5 and 7 (P< 0.004 for
both), while 100 mg/ml signiﬁcantly enhanced PG synthesisFig. 7. Effect of GluNH2, CS and mixtures on MMP-3 release in 10% serum conditions in the presence of the 29-kDa Fn-f. Cartilage was cul-
tured as in Fig. 5. Agents were added to cartilage in 10% serum cultures and after 4 h, Fn-f added. Media were changed at days 3 and 5.
Media that had been conditioned from days 5e7 were collected on day 7 and treated with Reactive Red 120-agarose to trap MMP-3 and leave
serum proteins behind. Without use of Reactive Red-agarose, visualization of MMP-3 was problematic. The washed resin was subjected to
denaturation buffer and releasate blotted against anti-MMP-3. Panels A, C and E show untreated control (C) and B, D and F show samples
with both Fn-f and agent present.
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effective at later times with 100 mg/ml with signiﬁcant effects
at day 14 (P¼ 0.004). Concentrations of 0.01, 0.1 and 1 mg/ml
had no signiﬁcant effect (data not shown). The GluNH2
curves were similar to untreated control data.
Next the effect of GluNH2 on blocking Fn-f mediated PG
synthesis suppression was tested. Figure 8(B) shows that
the MMP-3 generated Fn-f mixture suppressed PG synthe-
sis by day 2 (P< 0.0001), followed by a reparative re-
sponse of the cartilage as shown by slowly increasing PG
synthesis rates, as we have reported earlier54. However,
preincubation with 1 mg/ml GluNH2 for 4 h, followed by addi-
tion of Fn-f, reversed Fn-f activity by day 2 (P¼ 0.0068) with
signiﬁcant reduction through day 5 (P¼ 0.001) and day 7
(P¼ 0.01). A concentration of 10 mg/ml was more effective
at days 2 and 5 (P< 0.0007 for both) while 100 mg/ml was
even more effective at days 2, 5 and 7 (P< 0.0005 for
all). By day 10, the differences between Fn-f treatment
and the 100 mg/ml GluNH2 treatment were not signiﬁcantly
different, suggesting that the effects of GluNH2 are not great
enough to cause persistent blocking. Concentrations of
0.01 and 0.1 mg/ml were ineffective (data not shown).
Fig. 8. Effect of GluNH2, CS and mixtures in absence of Fn-f (panel
A) and of GluNH2 in presence ofMMP-3 generated Fn-f digest (panel
B) on PG synthesis. Cartilage in 10% serum was cultured in pres-
ence of 1, 10 or 100 mg/ml test agent and mixture and at various
times, cartilage subjected to labelingwith 35-S sulfate. After labeling,
cartilage was extracted with guanidine-HCl, the extracts dialyzed
and cpm/mg wet weight cartilage measured. In panel A, only those
lines that are distinct from the control are labeled. In panel B, the ef-
fects of the various concentrations of GluNH2 in the presence of Fn-f
weremeasured. A control of Fn-f alone (F(d0e21)) is also shown. All
values were normalized to untreated controls (100%).The effects of CS were tested next. Figure 9(A) shows
that CS weakly reversed PG synthesis suppression caused
by the Fn-f. Concentrations of 1 mg/ml (P¼ 0.01), or 10 mg/
ml (P¼ 0.0001) or 100 mg/ml (P¼ 0.0002) signiﬁcantly de-
creased Fn-f activity at day 2. The effect of 1 mg/ml was
lost by day 5, while 10 mg/ml showed a partial effect
(P¼ 0.021) and 100 mg/ml was completely effective at day
5 (P< 0.0001). The 100 mg/ml concentration continued to
decrease Fn-f activity through day 10 (P< 0.0001). Con-
centrations of 0.01 and 0.1 mg/ml were ineffective (data
not shown).
Fig. 9. Effect of CS (panel A) and mixtures (panel B) in presence of
MMP-3 generated Fn-f and effect of mixtures in previously dam-
aged cartilage (panel C) on PG synthesis. For panels A and B, cul-
tures were established as described in Fig. 8, panel B. For panel C,
cartilage was ﬁrst damaged with Fn-f for 7 days, the Fn-f removed
and then mixtures added at various concentrations at day 7. A con-
trol of Fn-f alone (F) is also shown. All values were normalized to
untreated controls (100%).
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10 or 100 mg/ml were all totally effective in blocking or de-
creasing Fn-f mediated PG synthesis suppression for up
to day 14 (P< 0.0004 at all days). The effects were also
greater than untreated control at days 7, 10 and 14
(P< 0.007 at all days). A concentration of 1 mg/ml had
a lesser effect for days 2, 5, 7 or 10 (P< 0.006 for all
days). A 0.1 mg/ml concentration was indistinguishable
from Fn-f treatment (shown), as well as a 0.01 mg/ml con-
centration (data not shown). The major difference between
the agent mixture and the single agents is that the mixture
at 10 and 100 mg/ml totally blocked Fn-f mediated PG
synthesis suppression at any time point during the culture,
while the single agents only had a short term effect.
We next tested whether this blocking effect would also
occur in experiments in which the cartilage was damaged
ﬁrst by the Fn-f, the Fn-f removed and the agents added.
Figure 9(C) shows that the Fn-f by itself had signiﬁcant
effects (P< 0.0001). After removal of the Fn-f at day 7
and addition of the mixtures, 1, 10 and 100 mg/ml concen-
trations reversed the effects of the Fn-f at day 14
(P¼ 0.01, 0.0007 and 0.0002, respectively). Therefore,
the proanabolic activity of the mixture can either occur dur-
ing the Fn-f mediated damage or after maximal damage has
been inﬂicted.
Discussion
GluNH2 and CS have been shown to have pain-alleviat-
ing effects when taken orally. One basic question has
been whether or not these agents also modify damaged
cartilage or the progression of damage. Whether or not an
agent has disease-modifying effects in OA depends on
the demonstration that it can slow progression, with pro-
gression measured by a surrogate for structural change.
Currently the only accepted surrogate in OA is joint space
narrowing (JSN), measured by X-ray63. Effects on JSN
have been shown for GluNH2
64,65, but until recently had
not been shown for CS. Michel et al.66 recently showed
that the same CS (CondroSulf) present in Cosequin and
Cosamin DS, when used in long-term treatment, was able
to retard radiographic progression in patients with OA of
the knee. This same measurement is being made in the on-
going GAIT study using the same source of CS. Thus, our
objective was to test whether in our explant model, effects
of these agents on protection of the cartilage matrix could
be demonstrated. If so, this might suggest similar effects
in human subjects. However, it should be noted that we
have shown some differences in how Fn-fs damage human
cartilage, as compared with bovine cartilage67, an observa-
tion that might suggest some caution in predicting that the
blocking activity of the agent mixture would be as signiﬁcant
on human cartilage as we demonstrate here for bovine
cartilage.
With the initiation of this study, there were few observa-
tions that demonstrated that these agents were effective
in blocking cartilage damage or repairing cartilage in vitro.
However, there have been many studies of effects of these
agents on cartilage tissue or other cells. Unfortunately,
none of these studies were of their effect on the most rele-
vant parameters, such as matrix content. Our objective was
to test the effects of the single agents and combinations in
a well deﬁned in vitro damage model consisting only of car-
tilage and Fn-f. While the overall effects must be weighed in
the ﬁnal analysis in human subjects, analysis in a single
type of tissue system provides us an opportunity to more
clearly observe certain chondrolytic or anti-chondrolyticeffects. We utilized a powerful damage system, one that
employs Fn-fs that have the capability of removing half of
the total PG within 7 days in culture50e55. Thus, agents
that block Fn-f mediated damage would have to have very
potent anti-catabolic or proanabolic activities.
Our initial studies were of serum-free conditions in which
anabolic effects mounted by the tissue would have been
lesser than in serum because of the absence of growth
factors or proteinase inhibitors. These conditions allowed
us to study effects mainly on catabolism. We did not ob-
serve signiﬁcant effects of the agents on the kinetics of
PG degradation in the presence of Fn-f, although higher
concentrations of the mixture appeared to increase the
rate of PG release. These data should be treated with
caution since other experiments showed that the mixture
enhanced PG synthesis and this newly synthesized PG
may have been released into the media and contributed
to the rates of PG release we measured. This contribution
to the rate would have obscured the observation of a
blocking effect.
In terms of effects on MMP-3 and -13 release in serum-
free conditions, we did observe an early slowing of the re-
lease of MMPs, but this effect was mostly lost by 3 days.
The temporary nature of this loss might have been due to
exhaustion of the added GluNH2 or CS, since these agents
were added only once, at the beginning of the culture. This
observation of effects on MMP release is consistent with
other observations of the ability of these agents to decrease
MMP expression. However, it should be noted that we
found effects at mg/ml concentrations, much lower than
typically reported. As examples, GluNH2 at 100 mg/ml
suppressed MMP release from normal chondrocytes and
synoviocytes but not from OA chondrocytes68, GluNH2 at
1e150 mM suppressed MMP-3 mRNA levels 18e65% in
human chondrocytes22 and GluNH2 at 2.5 mg/ml decreased
MMP-3 protein release25. Further, both GluNH2 and CS
were found to decrease MMP gene upregulation in IL-1
challenged bovine cartilage29. Our data are also consistent
with the reported ability of CS or GluNH2 to block cytokine
activities27,28, since cytokines are involved in Fn-f mediated
MMP upregulation51,52.
It should also be noted that we showed that in our serum-
free conditions in which no serum contained protease
inhibitors would be present, that the agents did not block
the activity of the MMPs involved in matrix PG degradation
in our Fn-f model, although they have been proposed to act
as MMP inhibitors21,32,34e36. However, the data in Fig. 2 in
which less proMMP-13 but more lower mass MMP-13 was
apparent when the culture was treated with the mixture
would be consistent with some type of inhibition of prote-
ases involved in proMMP-13 activation.
Subsequent studies with serum present allowed us to
study the combined effects of catabolism and anabolism.
We found that while the agents singly or in combination
did not block Fn-f mediated PG degradation in serum-free
conditions, in the presence of serum the agents were
more effective likely due to the presence of growth factors
in serum which may have facilitated the restoration of PG
or the maintenance of steady state levels of PG. The single
agents showed weak activity, while the mixture was very
active at low concentrations. When tested for reparative
activities, a similar trend was observed. Since serum also
contains proteinase inhibitors, the serum may have also
decreased the proteolytic potential enough such that the
enhanced anabolic effects of the test agents were more
capable of compensation. Another possible explanation
for the differences between our serum-free and serum
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free conditions may have reduced the activity of the test
agents through additional binding interactions that other-
wise might have been lessened by the presence of serum
proteins.
In order to provide some information on how the agents
might be decreasing Fn-f mediated catabolism, the
serum cultures were tested for MMP expression. Consis-
tent with our studies in serum-free conditions, the serum
conditions also showed an effect on decreasing MMP
expression, with the single agents appearing to be more
effective than the mixture. Since the mixtures were more
effective than the single agents in blocking PG de-
gradation and in restoring PG, the effects on MMP-3
release cannot explain the efﬁcacy of the mixture. It is
possible that the agents might be more effective on other
proteases involved in cartilage damage, however, we have
demonstrated that MMP-3 is largely responsible for PG
degradation in our Fn-f culture system60. It should also
be noted that we measured MMP-3 and -13 in the media.
We do not yet know if these agents also blocked MMP-3
transcription.
In terms of PG synthesis, the effects of the agents were
ﬁrst tested in the absence of Fn-f. CS by itself appeared
to enhance PG synthesis early in culture but not at later
time points, while the mixture was more effective later.
GluNH2 did not show signiﬁcant effects by itself. When
the agents were tested for their ability to reverse Fn-f medi-
ated PG synthesis suppression, the single agents at higher
concentrations did have some effect on Fn-f activity. CS at
100 mg/ml did totally block the effect of the Fn-f, while
GluNH2 appeared to be weaker. However, the mixture at
1 mg/ml was nearly as effective as 10 mg/ml CS and the mix-
ture at 1e100 mg/ml totally blocked Fn-f activity. Our obser-
vation of the ability of CS to stimulate synthesis of PG is
consistent with other reports12,13,17,33. Since the mixture
which was more effective at blocking PG depleting and
restoring PG was also more effective at enhancing PG
synthesis than were CS or GluNH2, it is possible that a major
explanation for efﬁcacy of the mixture is through reversal of
Fn-f mediated PG synthesis suppression.
The concept that suppressed MMP release does not
lead to blocking of Fn-f mediated damage, while reversal
of PG synthesis suppression does is interesting. This sup-
ports the notion we published earlier in which we showed
that while treatment of both human knee and ankle carti-
lage with Fn-fs results in enhanced MMP expression and
elevated aggrecan degradation neoepitopes, only knee
cartilage shows a decrease in PG content67. Further, we
found that PG synthesis suppression in knee cartilage is
more sensitive to Fn-fs than in ankle cartilage67. We pro-
posed that the major damaging mechanism of Fn-fs toward
human knee cartilage is through suppression of PG syn-
thesis and not through elevated MMPs67. In comparison,
we have shown that in bovine cartilage, antibodies to
MMP-3 slow Fn-f mediated damage60. We have also
shown that MMP inhibitors block Fn-f mediated damage
to bovine cartilage (unpublished). Perhaps these differ-
ences are due to species differences as we have dis-
cussed65. Enhanced MMP activity may be more
responsible for Fn-f mediated decreases in cartilage PG
content in bovine cartilage than in human knee cartilage.
However, the data presented here with bovine cartilage
suggest that blocking of MMP-3 or -13 expression by
GluNH2 and CS is not sufﬁcient for blocking of cartilage
PG losses. It is also possible that the single agents have
secondary negative effects that minimize the beneﬁcialeffects of blocking MMP release, while the mixture may
have fewer of these side effects.
Our data show that the mixture was much more powerful
than the single agents and that concentrations of down to
1 mg/ml of each agent in the mixture could totally block
Fn-f mediated PG decreases in cartilage PG content. The
effects were partial at 0.1 mg/ml but lost at 0.01 mg/ml.
Observation of blocking at such a low concentration may
address the preliminary conclusions that the agents by
themselves cannot be effective after oral ingestion because
of the dilution in the circulatory system. It should be noted
that our demonstration of activity in the 0.1e1 mg/ml range
is well within the windows reported for measured plasma
levels in different species of CS of 5e40 mg/ml17,38e41 and
of GluNH2 of 2e20 mg/ml
38,42e45.
Our observations are in accord with other observations17
and proposals48,49 that the mixture is much more effective
than the single components. Our data showed that (1)
0.1 mg/ml of the mixture was as effective as 100 mg/ml CS
in blocking Fn-f mediated damage; (2) 1 mg/ml of the mix-
ture was more effective than 100 mg/ml GluNH2 or CS in
promoting restoration of PG; and (3) 1 mg/ml of the mixture
was more effective than 10 mg/ml CS in blocking Fn-f medi-
ated PG synthesis suppression. Thus, there is at least one
order of magnitude difference in the potencies between the
single agents and the mixture.
Discussion of the dose dependencies of these agents
has to also consider observations that these agents may
have an afﬁnity for cartilage23,36. Thus, the serum levels
of these agents may greatly underestimate the cartilage
bound concentrations. We should also point out that we
only preincubated cartilage with these agents for 4 h prior
to addition of Fn-f. Since some of our experiments were
up to 21 days duration, some concentration into the tissue
might have occurred. Thus, we cannot be sure that our ﬁnal
tissue concentration is the same as the initial. This might
also explain the trend to show slightly beneﬁcial effects of
these agents later in culture.
Regardless of the mechanism, this work is among the
ﬁrst to show the effects of these agents in an explant
cartilage degeneration model in which a far downstream
correlate of cartilage damage, PG depletion and restoration
were studied. While the enhanced PG synthesis is consis-
tent with cartilage repair, it should be noted that increased
PG synthesis also occurs in early OA as well as during
conditions in which the Fn-f causes minimal damage to car-
tilage54. Thus, the increased PG synthesis we observed
may not actually lead to stable repair. Further studies will
be needed to conﬁrm stable restoration of PG and other
matrix components, restoration of structural integrity of the
matrix and cessation or decreases of enhanced catabolic
pathways. Our observations of the greater effects of the
mixtures, suggest that single formulations may be less ef-
fective as nutraceutical compounds. Lastly, the concentra-
tions of agents we found to be effective are actually lower
than the concentrations measured in plasma of different
species after oral ingestion of the agents17,38e45, further
suggesting that these compounds might be capable of alter-
ing chondrocyte metabolism even with dilution into the
circulatory system.
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